MK-1775

Catalog No.S1525

MK-1775 Chemical Structure

Molecular Weight(MW): 500.6

MK-1775 is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM in a cell-free assay; hinders G2 DNA damage checkpoint. Phase 2.

Size Price Stock Quantity  
In DMSO USD 238 In stock
USD 170 In stock
USD 270 In stock
USD 470 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • Panobinostat enhances the antitumor activity of MK-1775 in a BxPC-3 xenograft model. Tumor specimens were fixed in 10% formalin, embedded in paraffin, and cut into 4 μM-thick slides for H&E staining.

    Cancer Letters, 2015, 356(200): 656–668 . MK-1775 purchased from Selleck.

    Diagnostic AML blasts from patients either at first diagnosis or at relapse are equally sensitive to MK-1775. Freshly isolated cells from patient AML#10 were purified by standard Ficoll-Hypaque density centrifugation. AML#10, HL-60, and HL-60/Ara-C cells were treated with MK-1775 for 48 h. Whole cell lysates were subjected to Western blotting and probed with anti-p-CDK1, -CDK1, -p-CDK2, -CDK2, -γH2AX, or -β-actin antibody.

    J Hematol Oncol 2014 7:53. MK-1775 purchased from Selleck.

  • GH activates STAT5 and ERK in breast cancer cells. T47D cells were pretreated for 2 hours with vehicle (dimethylsulfoxide) or inhibitors for EGFR (AG1478, 15 uM) or JAK2 (AZD1480, 1 uM), followed by treatment with GH+E2 for 30 minutes.

    Endocrinology 2013 154(9), 3219-27. MK-1775 purchased from Selleck.

    (C) Nude mice bearing MDA-MB-231 xenograft tumors were treated with vehicle, MK-1775, cisplatin, or a combination of cisplatin and MK-1775 for 28 days and tumor volumes were measured. Data are presented as the mean of 8 tumors for each group ± SEM.

    Sci Rep, 2017, 7:43517. MK-1775 purchased from Selleck.

  • Histopathological assessment of tumor response to MK-1775 alone and in combination with gemcitabine in a patient-derived osteosarcoma mouse model. A. H&E-stained paraffin sections were prepared to assess microscopic features of cell death and differentiation representative micrographs of B. Ki67 shows high immunoreactivity in the control, MK-1775, and combination treatments compared to gemcitabine treatment. C. Cleaved-caspase 3 images show high immunoreactivity in the MK-1775 and combination treatments compared to vehicle and gemcitabine treatment. D. Slides stained for γH2AX show high immunoreactivity in gemcitabine, MK-1775, and combination treatments compared to controls. E. Slides stained for Cyclin A show higher immunoreactivity in gemcitabine but not in control, MK-1775 alone or in combination treatments.

    PLoS One 2013 8(3), e57523. MK-1775 purchased from Selleck.

    AZD1480 inhibits the JAK2/STAT3 pathway in vitro. HT29 cells were cultured in 24-well plates overnight and then treated with 1 uM AZD1480 for 2 h followed by 4 ng/ml, IL-6 for 2 h and the distribution of phosphorylated STAT3 was analyzed by immunofluorescence.

    Oncol Rep 2014 32(5), 1991-8. MK-1775 purchased from Selleck.

Purity & Quality Control

Choose Selective Wee1 Inhibitors

Biological Activity

Description MK-1775 is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM in a cell-free assay; hinders G2 DNA damage checkpoint. Phase 2.
Features The first reported Wee1 inhibitor.
Targets
Wee1 [1]
(Cell-free assay)
5.2 nM
In vitro

MK-1775 inhibits Wee1 kinase in an ATP-competitive manner. Compared to Wee1, MK-1775 displays 2- to 3-fold less potency against Yes with IC50 of 14 nM, 10-fold less potency against seven other kinases with >80% inhibition at 1 μM, and >100-fold selectivity over human Myt 1, another kinase that inhibits cyclin-dependent kinase 1 (CDC2) by phosphorylation at an alternative site (Thr14). By abrogating the DNA damage checkpoint via blockade of Wee1 activity in WiDr cells bearing mutated p53, MK-1775 treatment inhibits the basal phosphorylation of CDC2 at Tyr15 (CDC2Y15) with EC50 of 49 nM, and suppresses gemcitabine-, carboplatin- or cisplatin-induced phosphorylation of CDC2 and cell cycle arrest in a dose-dependent manner, with EC50 of 82 nM and 81 nM, 180 nM and 163 nM, as well as 159 nM and 160 nM, respectively. MK-1775 treatment alone at 30-100 nM has no significant antiproliferative effect in WiDr and H1299 cells, whereas MK-1775 at 300 nM, sufficient to inhibit Wee1 by >80%, displays moderate but significant antiproliferative effects by 34.1% in WiDr cells and 28.4% in H1299 cells. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
ASPC-1 NVm5R5hST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zQcGlEPTB;MUOuNkDDuSBzLkGg{txO Mm\TNlU1PTh7NUS=
BxPC-3 NXHEOHJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwODFCtUAxNjB|IN88US=> NUXzbWRTOjV2NUi5OVQ>
CFPAC-1 MnnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfaTWM2OD1|LkOgxtEhOC5{IN88US=> NYLKNpk5OjV2NUi5OVQ>
HPAC NWjlcHptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwNTFCtUAxNjBzIN88US=> Ml7FNlU1PTh7NUS=
MIAPaCa-2 NUnNWllbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrDWFNKSzVyPUCuOUDDuSByLkC1JO69VQ>? MknXNlU1PTh7NUS=
PANC-1 NYfhNo9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIi5VW1KSzVyPUGwMlYhyrFiMT6xJO69VQ>? NIr4SVUzPTR3OEm1OC=>
SK-N-BE (2) MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\h[GlEPTB;Mj605qCKyrIkgJmwMlMh|ryP NFzLOpMzPTNyOEmxOi=>
SK-N-BE (2), PAN→MK MkWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPRO4xKSzVyPUK2MlbjiIoEsfMAjVkvPiEQvF2= M1zUPFI2OzB6OUG2
SK-N-BE (2), MK→PAN NIHVRVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXNTWM2OD1{LkVihKnDueLCiUCuN{DPxE1? Mn[1NlU{ODh7MU[=
SK-N-AS NX33NVgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLISYZKSzVyPUCuOVDjiIoEsfMAjVAvODJizszN MXyyOVMxQDlzNh?=
SK-N-DZ NVv6S5VWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPDPFRFUUN3ME2wMlM36oDLwsJihKkxNjBzIN88US=> MUeyOVMxQDlzNh?=
SK-N-AS MY\BdI9xfG:|aYOgRZN{[Xl? M4Xp[VUxOCCwTR?= M2fKXVQ5KGh? M3TkPIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NFzDfmozPTNyOEmxOi=>
SK-N-DZ MUnBdI9xfG:|aYOgRZN{[Xl? MWK1NFAhdk1? NV;0[4RVPDhiaB?= MlfIbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MnrkNlU{ODh7MU[=
THP-1 MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TzSFEzPS9{NUCvOVAxKG6P NIPOWZE1QCCq MnHJbY5kemWjc3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NYK0fmlTOjVyOES2NVQ>
MV4-11 MlfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWCxNlUwOjVyL{WwNEBvVQ>? NYn2PI5EPDhiaB?= MVXpcoNz\WG|ZYOgZ4VtdCCmZXH0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> MkHnNlUxQDR4MUS=
U937 M3rtSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH24TI4yOjVxMkWwM|UxOCCwTR?= MnnjOFghcA>? NGT0OGVqdmO{ZXHz[ZMh[2WubDDk[YF1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NFPhcFgzPTB6NE[xOC=>
HL-60 MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXuxNlUwOjVyL{WwNEBvVQ>? M{HmOFQ5KGh? NXX4b3F2cW6lcnXhd4V{KGOnbHyg[IVifGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? MYOyOVA5PDZzNB?=
OCI-AML3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\Pd|EzPS9{NUCvOVAxKG6P MlTuOFghcA>? MWHpcoNz\WG|ZYOgZ4VtdCCmZXH0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> MXOyOVA5PDZzNB?=
MOLM-13 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLTNVI2NzJ3MD:1NFAhdk1? NGTTflA1QCCq NIDRZ3dqdmO{ZXHz[ZMh[2WubDDk[YF1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? M3\LO|I2ODh2NkG0
CMK MXXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUXsSYZNOTBvMUCwNFAhdk1? MVG3NkBp NEC5TFZz\WS3Y3XzJINmdGxidnnhcIljcXS7IHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ M4jOUlI1QTZ{M{Ox
CMY MojkR4VtdCCYaXHibYxqfHliQYPzZZk> NHPyfnMyOC1zMECwNEBvVQ>? M2nv[|czKGh? Mnn6doVlfWOnczDj[YxtKH[rYXzpZol1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? MY[yOFk3OjN|MR?=
Dayo MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;hdlhKSzVyPUG1NEBvVQ>? Mn;MNlQ3PjF7MUC=
UW228 NUDjNIszT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TnPGlEPTB;MkOyJI5O M1\3bFI1PjZzOUGw
IST-MES1 NF\sb3pE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NF\zNGkyPTBxMkWwJI5O MXO3NkBp Ml72[Y5p[W6lZYOgeIhmKGOrc4DsZZRqdiCleYTveI95cWNiZX\m[YN1KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NFyzXpUzPDN4NUe4Ni=>
IST-MES2 M1G5RWNmdGxiVnnhZoltcXS7IFHzd4F6 M2nBRVE2OC9{NUCgcm0> NH36V4o4OiCq NGPnVWJmdmijbnPld{B1cGViY3nzdIxifGmwIHP5eI91d3irYzDl[oZm[3RiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? MnSyNlQ{PjV5OEK=
REN NXXibZROS2WubDDWbYFjcWyrdImgRZN{[Xl? NV2weWJ4OTVyL{K1NEBvVQ>? MUi3NkBp NIHnNJRmdmijbnPld{B1cGViY3nzdIxifGmwIHP5eI91d3irYzDl[oZm[3RiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? MleyNlQ{PjV5OEK=
NCI-H2452 M4nITmNmdGxiVnnhZoltcXS7IFHzd4F6 MoXINVUxNzJ3MDDuUS=> NHvTTZI4OiCq MYPlcohidmOnczD0bIUh[2m|cHzheIlvKGO7dH;0c5hq[yCnZn\lZ5QhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NWTvSIIzOjR|NkW3PFI>
MSTO-211H M2THU2NmdGxiVnnhZoltcXS7IFHzd4F6 M2LETVE2OC9{NUCgcm0> M4LCXFczKGh? NYmxSJVo\W6qYX7j[ZMhfGinIHPpd5Bt[XSrbjDjfZRwfG:6aXOg[YZn\WO2IHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ NIr5XFIzPDN4NUe4Ni=>
NCI-H2052 MWPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{TQWlE2OC9{NUCgcm0> NIGwenY4OiCq NIDTPGNmdmijbnPld{B1cGViY3nzdIxifGmwIHP5eI91d3irYzDl[oZm[3RiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? NYjKPWt5OjR|NkW3PFI>
WEE1 M2PBcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jnfmlEPTB;NT6yJI5O NYDkUWRYOjN4OUm2OVU>
CDC2 NVPXcpJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfxd4J2UUN3MP-8olExODBibl2= NYqzdWV7OjN4OUm2OVU>
CDK7 M3K3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfSPJR1UUN3MP-8olExODBibl2= MkPYNlM3QTl4NUW=
MYT1 NY\2O|lGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTV|MDDuUS=> M4XES|I{Pjl7NkW1
T98G  NUSwfHJkSXCxcITvd4l{KEG|c3H5 NWDoflFQOTByL{K1NEBvVQ>? MlfqOkBp NGLZR2xmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBk\WyuIHvpcIxqdmd? M2XCc|IyQTl{N{mz
A549 NH\MTpRCeG:ydH;zbZMhSXO|YYm= NYr4Z5AyOjByIH7N M3XVe|EhcA>? NXGwem1wemGmaX;z[Y5{cXSrenXzJG5US0yFIHPlcIx{KGmwIHGgdFU{NWSncHXu[IVvfCCvYX7u[ZI> M3f4U|IyPzl7MEOz
H460 M{XsUmFxd3C2b4Ppd{BCe3OjeR?= M3vNdVIxOCCwTR?= NHrBNW4yKGh? M1;mOZJi\Gmxc3Xud4l1cXqnczDOV2NNSyClZXzsd{BqdiCjIIC1N{1l\XCnbnTlcpQhdWGwbnXy NVPEXFg4OjF5OUmwN|M>
H1299 M3\mUmFxd3C2b4Ppd{BCe3OjeR?= M{LoblIxOCCwTR?= M3HjTFEhcA>? MV\yZYRqd3OnboPpeIl7\XNiTmPDUGMh[2WubIOgbY4h[SCyNUOt[IVx\W6mZX70JI1idm6nch?= Mnm0NlE4QTlyM{O=
Calu-6  M3e1cmFxd3C2b4Ppd{BCe3OjeR?= Mn;MNlAxKG6P MmD1NUBp NHvQNYtz[WSrb4PlcpNqfGm8ZYOgUnNEVENiY3XscJMhcW5iYTDwOVMu\GWyZX7k[Y51KG2jbn7ldi=> Mn75NlE4QTlyM{O=
WiDr MoDaT4lv[XOnIFHzd4F6ew>? MWWxNE0yODByMDDuUS=> MoXpPEBp MV3pcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gR2REOiCjdDDUfZIyPSC5aYToJIFvKEWFNUFCpJZidHWnIH;mJFg2KG6vb3yvUEBxemW2cnXheIVlKHerdHig[4Vu[2m2YXLpcoU> NYq3SIl[OTl6OEe1OFU>

... Click to View More Cell Line Experimental Data

In vivo MK-1775 treatment alone at ~20 mg/kg displays minimal antitumor effects against WiDr xenografts in rats with T/C of 69% at day 3. Antitumor efficacy by MK-1775 alone in the nude rat HeLa-luc and TOV21G-shp53 xenograft models is also moderate. [1]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro kinase assays:

Recombinant human Wee1 is used. Kinase reaction is conducted with 10 μM ATP, 1.0 μCi of [γ-33P]ATP, and 2.5 μg of poly(Lys, Tyr) as a substrate in the presence of increasing concentrations of MK-1775 at 30°C for 30 minutes. Radioactivity incorporated into the substrate is trapped on MultiScreen-PH plates and is counted on a liquid scintillation counter.
Cell Research:

[1]

+ Expand
  • Cell lines: WiDr, NCI-H1299, TOV21G, and HeLa
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are treated with or without gemcitabine for 24 hours, then with MK-1775 for an additional 24 hours. Cell viability is determined with a WST-8 kit using SpectraMax. Cellular caspase-3/7 activities are determined with a Caspase-3/7 Glo kit.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Immunodeficient nude rats (F344/NJcl-rnu) bearing WiDr, HeLa-luc, or TOV21G-shp53 tumors
  • Formulation: Prepared in a vehicle of 0.5% methylcellulose solution
  • Dosages: ~20 mg/kg/day
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 80 mg/mL (159.8 mM)
Ethanol 10 mg/mL (19.97 mM)
Water 0.0001 mg/mL (0.0 mM)
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 500.6
Formula

C27H32N8O2

CAS No. 955365-80-7
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02037230 Recruiting Adenocarcinoma of the Pancreas University of Michigan Cancer Center January 2014 Phase 1|Phase 2
NCT01357161 Completed Ovarian Cancer Merck Sharp & Dohme Corp. July 2011 Phase 2
NCT01164995 Unknown status Epithelial Ovarian Cancer The Netherlands Cancer Institute|Merck Sharp & Dohme Corp. July 2010 Phase 2
NCT01076400 Terminated Cervical Cancer Merck Sharp & Dohme Corp. May 2010 Phase 1|Phase 2
NCT01047007 Terminated Solid Tumors Merck Sharp & Dohme Corp. January 2010 Phase 1
NCT00648648 Completed Solid Tumors Merck Sharp & Dohme Corp. February 2008 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to prepare MK1775 methylcellulose solution? and how to prepare methylcellulose itself? Once make the MK1775 methylcellulose solution, how should i keep it?

  • Answer:

    MK1775 in 0.5% methylcellulose is a suspension or emulsion, and it is ok to treat mice orally. It is recommended to dissolve methylcellulose in saline. It will take some time to dissolve methylcellulose, and you can vortex it for a while. The MK1775 methylcellulose solution can be stored at 4°C for a week.

Wee1 Signaling Pathway Map

Related Wee1 Products

Tags: buy MK-1775 | MK-1775 supplier | purchase MK-1775 | MK-1775 cost | MK-1775 manufacturer | order MK-1775 | MK-1775 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID